Acipimox

Oral
Hyperlipidaemias

CrCl (mL/min)	Dosage
<30	Contraindicated.
30-60	250 mg 1-2 times daily.

Should be taken with food. Take w/ or after meals.

Peptic ulcer. Severe renal impairment (CrCl <30 mL/min).

Renal impairment (CrCl 30-60 mL/min).

Peripheral vasodilatation, resulting in flushing, itching and sensation of heat; rash, erythema, heartburn, epigastric pain, nausea, diarrhoea, headache, myalgia, arthralgia, dry eye, malaise, myositis. Rarely, urticaria, angioedema, bronchospasm.

Monitor hepatic and renal function. Measure lipid profile before treatment and serum lipids periodically.

Risk of myopathy is increased when nicotinic acid is given concomitantly w/ a statin, as acipimox is structurally related to nicotinic acid, caution should be taken when used w/ such agents.

Description: Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of VLDL and LDL w/ a subsequent overall reduction in triglyceride and cholesterol levels.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the GI tract. Time to peak plasma concentration: W/in 2 hr.
Excretion: Via urine. Plasma half-life: Approx 2 hr.

Dyslipidaemic Agents

C10AD06 - acipimox ; Belongs to the class of nicotinic acid and derivatives. Used in the treatment of hyperlipidemia.

Anon. Acipimox. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/06/2016.

Buckingham R (ed). Acipimox. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/06/2016.

Joint Formulary Committee. Acipimox. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/06/2016.

Pfizer New Zealand Ltd. Olbetam 250 mg Capsules data sheet 08 January 2014. Medsafe. http://www.medsafe.govt.nz/. Accessed 10/06/2016.